Business
Our product, Qelbree, is a novel nonstimulant taken once-daily for full-day exposure.
SUPERNUS PHARMACEUTICALS, INC.: Revenue grew 8.6% to $719M from $662M. Net income turned into a $38.55M loss from $73.86M of profit. Free cash flow declined 73.1% to $45.99M from $171M. Operating margin contracted 2100 bps to -8.66%. SUPERNUS PHARMACEUTICALS, INC.'s annual comparison also shows free cash flow declined despite revenue growth; margins improved while free cash flow declined; stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 8.6% to $719M from $662MOK
- Profitability — Net income turned into a $38.55M loss from $73.86M of profitWatch
- Cash flow — Free cash flow declined 73.1% to $45.99M from $171MWatch
- Margins — Operating margin contracted 2100 bps to -8.66%Watch
- Accounting — Cash quality needs scrutinyWatch
- Insiders — 0 purchases and 36 salesWatch
Where the revenue comes from
Fiscal 2025, as SUPERNUS PHARMACEUTICALS, INC. reports it. History and quarterly detail are in the app.
- Net product sales$626.5M
- Collaboration revenue (ZURZUVAE)$53.0M
- Royalty, licensing, and other revenues$39.4M
Leadership changes
From SUPERNUS PHARMACEUTICALS, INC.'s own filings, the day they're filed.
- Regulatory Affairs · departureeff. 2024-05-03
- Roman Bradel · President · departureeff. 2024-05-03
- Bethany L. Sensenig · member · appointment
Latest filings
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-08-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SUPERNUS PHARMACEUTICALS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.